Effects of Bilateral Quadratus Lumborum Block and Transversus Abdominis Plane Block on Postoperative Analgesia and Serum Inflammatory Factors in Women Undergoing Cesarean Section
TANG Hui, LI Bin, HUANG Wei
Department of Anesthesiology, Changning District Maternal and Child Health Hospital, Shanghai 200050
Abstract：【Objective】 To investigate the effects of bilateral quadratus lumborum block (B-QLB) and transversus abdominis plane block (TAPB) on postoperative analgesia and serum levels of monocyte chemoattractant protein-1 (MCP-1), substance P (SP), and 5-hydroxytryptamine (5-HT) in women undergoing cesarean section. 【Methods】 A total of 200 women scheduled for cesarean section were randomly assigned to the control group (n=100, TAPB) and the observation group (n=100, B-QLB). Analgesic efficacy, clinical recovery parameters, resting and movement visual analogue scale (VAS) scores at 4 h, 8 h, 12 h, 24 h, and 48 h postoperatively, serum biomarkers (MCP-1, SP, 5-HT), and adverse events were compared between the two groups. 【Results】 Resting VAS scores showed no significant differences between the two groups (P>0.05). The observation group had lower movement VAS scores at 8 h, 12 h, 24 h, and 48 h (P<0.05). The first pressing time of the analgesia pump in the observation group was longer than that in the control group. The number of effective pressings and the analgesia rescue rate 24 after surgery were lower than those in the control group, and the analgesia satisfaction score was higher than that in the control group (all P<0.05). The observation group also showed shorter times to first standing, first ambulation, and onset of lactation (all P<0.05). Postoperative serum MCP-1, SP, and 5-HT levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions did not differ significantly between groups (P>0.05). 【Conclusion】 Compared with TAPB, B-QLB provides superior postoperative analgesia effect for cesarean section, reduces analgesic consumption, significantly lowers serum MCP-1, SP, and 5-HT levels, and does not increase the risk of adverse events.
2026, Vol. 43 
